ASRT
Assertio Holdings Inc

15,739
Mkt Cap
$74.05M
Volume
31,194.00
52W High
$15.15
52W Low
$7.71
PE Ratio
-2.45
ASRT Fundamentals
Price
$11.54
Prev Close
$11.62
Open
$11.76
50D MA
$11.38
Beta
1.34
Avg. Volume
38,453.93
EPS (Annual)
-$3.40
P/B
0.70
Rev/Employee
$2.15M
$23.20
Loading...
Loading...
News
all
press releases
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
Plus (PSTV) delivered earnings and revenue surprises of +100.00% and +2.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
Zacks·9d ago
News Placeholder
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
Zacks·9d ago
News Placeholder
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.
Zacks·10d ago
News Placeholder
Assertio (ASRT) Projected to Post Quarterly Earnings on Wednesday
Assertio (NASDAQ:ASRT) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 11. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
Assertio Holdings, Inc. (Assertio) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following...
Business Wire·11d ago
News Placeholder
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
Zacks·12d ago
News Placeholder
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Zacks·15d ago
News Placeholder
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Perrigo misses Q4 EPS estimates. Its 2026 sales and profit estimates are below expectations as Infant Formula headwinds persist. Shares slide on weak guidance.
Zacks·15d ago
News Placeholder
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·15d ago
<
1
2
...
>

Latest ASRT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.